Mamolo C, Welch V, Walter RB, Cappelleri JC, Brockbank J, Cawson M, Knight C, Wilson M. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. Pharmacoeconomics. 2021 Jan;39(1):121-31. doi: 10.1007/s40273-020-00976-6
Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, Jayasundara K. Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada. Pharmacoeconomics. 2016 Jan;34(1):77-90. doi: 10.1007/s40273-01509332-5
Poonawalla IB, Parikh RC, Du XL, VonVille HM, Lairson DR. Cost effectiveness of chemotherapeutic agents and targeted biologics in ovarian cancer: a systematic review. Pharmacoeconomics. 2015 Nov;33(11):1155-85. doi: 10.1007/s40273-015-0304-9
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. Pharmacoeconomics. 2014 Oct;32(10):1005-13.
Earnshaw SR, Brogan AP, McDade CL. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges. Pharmacoeconomics. 2013 Apr 1;31(4):289-304.
Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics. 2010 Nov 1;28(11):1025-39.
Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 Jun 1;28(6):489-505.
Beard SM, Wall L, Gaffney L, Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004 Jan 1;22(4):207-24.
Sculpher M, Palmer MK, Heyes AE. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000 Apr;17(4):361-70.